Avelox in Complicated Skin and Skin Structure Infections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6127 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-10-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions. Specifically investigated are the improvement of clinical symptoms and the duration until infection improvement and cure.Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) treated with Avelox can be documented. The observation period for each subject covers the treatment period with Avelox. For each patient, the physician documents data at an initial visit and one or two follow-up visit(s) in line with routine practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Diseases, Bacterial

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Skin Diseases, Bacterial Product Surveillance Postmarketing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Moxifloxacin (Avelox, BAY12-8039)

Intervention Type DRUG

400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moxifloxacin (Avelox, BAY12-8039)

400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) and for whom the decision was made by the attending physician to start treatment with Avelox before inclusion into and independent of the study.

Minimum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bayer HealthCare AG

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Austria

Site Status

Many Locations, , Bulgaria

Site Status

Many Locations, , Egypt

Site Status

Many Locations, , Germany

Site Status

Many Locations, , Greece

Site Status

Many Locations, , Indonesia

Site Status

Many Locations, , Pakistan

Site Status

Many Locations, , Philippines

Site Status

Many Locations, , Saudi Arabia

Site Status

Many Locations, , Slovenia

Site Status

Many Locations, , South Korea

Site Status

Many Locations, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Bulgaria Egypt Germany Greece Indonesia Pakistan Philippines Saudi Arabia Slovenia South Korea Taiwan